Sexual & reproductive health

A couple of peptides are studied in sexual and reproductive contexts, working through very different mechanisms and with very different safety profiles.

Kisspeptin is a neuropeptide that sits at the top of the reproductive (hypothalamic-pituitary-gonadal) axis, stimulating GnRH and downstream LH/FSH. It has a comparatively strong body of human academic research, including studies in fertility, IVF, and the brain's processing of sexual and emotional cues, but it remains investigational and is not an approved consumer product. Melanotan II is a melanocortin agonist whose side effect of spontaneous erections led to interest in erectile function (and to the development of the separate, approved drug bremelanotide / PT-141). Melanotan II itself is not approved anywhere and carries a serious risk profile (priapism, nausea, mole/melanoma concerns, and more).

Conditions people ask about

Popular videos in this area promise to "reverse" perimenopause, "cure" PCOS, "shrink" endometriosis or an enlarged prostate, and "boost" fertility with peptides. That framing is not supported: no compound on this site is an approved treatment for any condition below, and dramatic reversal or cure claims lack controlled human evidence. The notes here exist to answer common searches honestly, not to guide treatment — every condition below is a matter for a licensed clinician and proper diagnosis, and a research peptide is not a substitute.

Menopause and perimenopause

High-claim content markets peptides as a "natural" or "next-generation" way to reverse perimenopause and restore hormones while sidestepping conventional hormone therapy. In reality, no peptide in this inventory is an approved treatment for menopause or perimenopause; the licensed options remain hormone therapy and non-hormonal drugs prescribed by a clinician, and none of the peptides discussed has controlled human trial evidence that it treats menopausal decline itself [Human]. In this context you'll see PT-141, FDA-approved (as Vyleesi, 2019) only for acquired hypoactive sexual desire disorder in premenopausal women [Human] — it is not a menopause treatment, use in postmenopausal women is off-label with a thinner evidence base, and it does nothing for the hormonal decline of menopause; MOTS-c, discussed only because its circulating levels fall in postmenopausal women in observational data [Human] — an association, not a treatment, with no clinical trials in menopausal women and most data animal- or cell-based [Animal]; and Epitalon, marketed in the community as a "longevity"/sleep peptide sometimes tied to hormonal aging, with no controlled human evidence it treats menopausal or perimenopausal symptoms [Hypothesis]. Menopause and perimenopause are clinical diagnoses that require a licensed clinician; a research peptide is not a substitute.

PCOS (polycystic ovary syndrome)

Popular videos frame GLP-1 peptides as a way to "cure" or "reverse" PCOS by fixing insulin resistance and restarting ovulation. No peptide here is approved specifically to treat PCOS, which is managed by a clinician — often with lifestyle measures and drugs such as metformin or hormonal therapy; the GLP-1 compounds discussed are approved for type 2 diabetes and obesity, and while trials show weight loss and improved insulin sensitivity that may support more regular cycles, PCOS-specific studies are small and outcomes vary [Human]. Discussed in this context are Semaglutide, a GLP-1 agonist approved for type 2 diabetes and obesity (not PCOS), studied here because weight loss and improved insulin sensitivity are being examined for whether they indirectly influence metabolic and menstrual features, without targeting the syndrome's underlying cause [Human]; Tirzepatide, a dual GIP/GLP-1 agonist approved for diabetes and obesity that produces larger weight loss than semaglutide in head-to-head obesity trials [Human] but whose PCOS benefit is inferred from weight/insulin effects and remains investigational; Liraglutide, an older GLP-1 agonist approved for diabetes and obesity, studied in small PCOS trials for weight and metabolic endpoints but not approved for PCOS and not a treatment for the underlying disorder [Human]; and Kisspeptin, a reproductive-axis peptide studied experimentally in ovulation and IVF settings, including in PCOS patients at high OHSS risk [Human] — investigational, not an approved therapy, and not a self-administered "fix." PCOS requires a proper diagnosis by a licensed clinician; a research peptide is not a substitute.

Endometriosis

The community sometimes promotes healing or anti-inflammatory peptides as a way to shrink endometriosis lesions or avoid hormonal drugs and surgery. No peptide in this inventory is an approved treatment for endometriosis, and dramatic "lesion-reversal" claims lack controlled human evidence; the approved GnRH-based drugs for endometriosis (leuprolide, goserelin, nafarelin) are long-acting GnRH agonist analogs that suppress estrogen, and none of those is in this inventory. Discussed here are Gonadorelin, which is native GnRH — a short-acting decapeptide that, given in pulses, stimulates the reproductive axis rather than shutting it down; it is not the long-acting GnRH-agonist class used to suppress estrogen in endometriosis, it is not an endometriosis therapy, and conflating it with GnRH-agonist drugs is a common error — and BPC-157, a synthetic peptide promoted as an all-purpose "healing/anti-inflammatory" agent (including for pelvic pain) whose evidence is essentially preclinical (roughly one human study; not approved by any regulator), with no controlled human evidence it affects endometriosis [Animal][Hypothesis]. Endometriosis needs diagnosis and management by a licensed clinician (often gynecology/surgery); a research peptide is not a substitute.

Enlarged prostate (BPH)

High-claim content suggests healing or "regenerative" peptides can shrink an enlarged prostate or resolve urinary symptoms without conventional medication. No peptide in this inventory is an approved treatment for benign prostatic hyperplasia; BPH is managed by a clinician with proven drugs (alpha-blockers, 5-alpha-reductase inhibitors) or procedures, and the peptides discussed here are either bioregulator products marketed with prostate branding but without controlled human efficacy data, or general "healing" peptides with no BPH evidence. Discussed are Prostamax, a peptide "bioregulator" marketed by name for prostate health whose claims rest on manufacturer-associated bioregulator literature rather than independent controlled human trials, with no robust evidence it treats BPH [Hypothesis]; and BPC-157, a general "healing" peptide sometimes mentioned for pelvic/urinary complaints whose evidence is preclinical and unapproved by any regulator, with no controlled human evidence for any effect on prostate size or BPH symptoms [Animal][Hypothesis]. Urinary symptoms can also signal other conditions, so BPH needs a proper diagnosis by a licensed clinician; a research peptide is not a substitute.

Fertility and IVF

Popular content claims peptides can "boost fertility," restart ovulation, or improve IVF success as a do-it-yourself alternative to fertility clinics. Fertility care and IVF are delivered by licensed reproductive specialists, and self-administering research peptides can interfere with a monitored cycle; none of these compounds is an approved consumer fertility treatment. The most genuinely studied here is Kisspeptin, a reproductive-axis peptide with real Phase 2 human IVF data as a trigger of egg maturation, associated with pregnancies/live births and potentially lower ovarian hyperstimulation syndrome risk than standard triggers [Human] — still investigational, not approved, and only meaningful inside a monitored IVF cycle. Also discussed is Gonadorelin, native GnRH historically used in supervised, pump-delivered pulsatile protocols to induce ovulation in specific hypothalamic infertility cases [Human] — a clinician-managed medical use, not a general fertility booster, where unsupervised use can disrupt rather than help a cycle. Fertility problems need diagnosis and management by a licensed clinician; a research peptide is not a substitute.